Encapsulated cell therapy delivering ciliary neurotrophic factor (NT-501) reduces photoreceptor degeneration in MacTel type 2, demonstrated in rigorous, multicenter phase 3 randomized controlled trials.
NT-501 treatment significantly slowed ellipsoid zone area (EZA) loss over 24 months, a key biomarker of photoreceptor integrity, compared to sham controls.
Despite robust structure preservation, functional outcomes such as retinal sensitivity, reading speed, and patient-reported vision-related quality of life showed inconsistent improvement.
NT-501 exhibited an acceptable safety profile, with transient miosis and delayed dark adaptation as the most notable adverse events, but no significant increase in serious adverse events or visual acuity loss.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.